LON:FARN Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis GBX 41.50 +0.50 (+1.22%) As of 08:29 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Faron Pharmaceuticals Oy Stock (LON:FARN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get FARN alerts:Sign Up Key Stats Today's Range 41▼ 41.5050-Day Range 38.10▼ 4752-Week Range 38▼ 240Volume11,096 shsAverage Volume127,181 shsMarket Capitalization£84.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com Read More Receive FARN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FARN Stock News HeadlinesFaron Uses Treasury Shares to Settle EUR 1.58m Convertible Bond AmortisationAugust 3, 2026 | tipranks.comFaron posts encouraging survival signal in bexmarilimab HR-MDS trialJuly 27, 2026 | tipranks.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 13 at 1:00 AM | Chaikin Analytics (Ad)Faron Pharmaceuticals Grants 2.17 Million Share Options Under 2026 Incentive PlanJuly 1, 2026 | tipranks.comFaron Registers New Treasury Shares to Support Potential Bond ConversionsJune 11, 2026 | tipranks.comSeveral Insiders Invested In Faron Pharmaceuticals Oy Flagging Positive NewsJune 5, 2026 | finance.yahoo.comFaron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary CommitteeJune 5, 2026 | finance.yahoo.comFaron Pharmaceuticals Fined by Nasdaq Helsinki Over Disclosure DelaysJune 5, 2026 | tipranks.comSee More Headlines FARN Stock Analysis - Frequently Asked Questions How have FARN shares performed this year? Faron Pharmaceuticals Oy's stock was trading at GBX 179 at the beginning of the year. Since then, FARN stock has decreased by 76.8% and is now trading at GBX 41.50. How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:FARN CIKN/A Webwww.faron.com Phone+358-2-4695151FaxN/AEmployees34Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (22.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£60.23 million Net MarginsN/A Pretax MarginN/A Return on Equity45.13% Return on Assets-70.00% Debt Debt-to-Equity Ratio-133.35 Current Ratio0.84 Quick Ratio1.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 2.08 per share Price / Cash Flow20.00 Book ValueGBX 1,957.36 per share Price / Book0.02Miscellaneous Outstanding Shares202,881,000Free FloatN/AMarket Cap£84.20 million OptionableNot Optionable Beta1.12 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:FARN) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
